Hemophilia is a bleeding disorder that afflicts about 1 in 5000 males. Treatment relies upon
replacement of the deficient factor, and response to treatment both in clinical research and …

Hemophilia A and B are rare inherited bleeding disorders resulting from deficiency of
coagulation factors VIII and IX respectively. In the past few decades, the field of hemophilia …

BACKGROUND Until recently, clinical laboratories have monitored hemophilia treatment by
measuring coagulation factors before/after infusion of human-derived or recombinant …

INTRODUCTION: Global coagulation tests may have a better relation with phenotype in
haemophilia than traditional coagulation tests. These include the Calibrated Automated …

Currently, there is no single haemostasis laboratory test that has the capacity to accurately
illustrate the clinical effects of procoagulant or anticoagulant interventions. Although the time …

Precise measurements of factor VIII (FVIII) or factor IX (FIX) activity are believed to be
essential for clinical management in haemophilia, although discrepancies between factor …

BACKGROUND: Hemophilia A (HA) patients with similar factor VIII levels can demonstrate
varying bleeding tendencies. In particular, 10–15% of all severe HA patients (FVIII: C< …

Factor VIII bypassing agents have different multiple modes of action, but share the common
feature of inducing or facilitating thrombin generation. The information obtained from most …

Hellmut Hartert was the first person to exploit the viscoelastic properties of clotting blood to
measure blood coagulation in 1948. Since then, the technology has improved, allowing …

Thrombin generation is a key process that determines the extent of a hemostatic plug or a
thrombotic process. The ensuing thrombin burst is crucial for the formation of a stable fibrin …